In addition to improving insulin resistance of these mTOR parameters, simufilam has improved insulin receptor signaling both in postmortem AD brain and in AD mouse models, although not to normal levels (Wang et al., 2012; Wang et al., 2017). Here, MTOR is linked to Alzheimer disease.